827 / 1835
PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin
Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and
Biomarker Assessment
Philippe Armand, et al Blood 2015 126:584
•
ORR among the 31 patients was 65% (90% CI, 48-79).
•
Five patients achieved CR (16%), 15 partial remission (48%), and 7 (23%)
stable disease as their best response.
•
With a median follow-up of 9.7 (1.3-17.5) months, median DOR not been
reached (0+ to 13.4+ months).
•
As of the data cut-off, 14 patients (45%) remained on treatment; 2 (6%)
patients discontinued for toxicity, 12 (39%) for progression, and 3 (10%)
for other reasons.
•
Of the 20 responses, 14 are ongoing.